Search

Displaying results 2091 - 2100 of 9667 in total
  1. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    [A199026] Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics. … [A199026] Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permeability of the connective tissue.

  2. Drug

    Perflubutane

    go.drugbank.com/drugs/DB12821
    ApprovedInvestigationalWithdrawn

    Perflubutane has been used in trials studying the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and Peripheral Artery Disease. … It is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease.

  3. Drug

    Triethylenetetramine

    go.drugbank.com/drugs/DB06824
    ApprovedInvestigational

    Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. … TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925.

  4. Drug

    Romidepsin

    go.drugbank.com/drugs/DB06176
    ApprovedInvestigational

    Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy

  5. Drug

    Picosulfuric acid

    go.drugbank.com/drugs/DB09268
    ApprovedInvestigational

    The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.[A33322]

    Products: MOTILAXIL-T
  6. Drug

    N-acetyltyrosine

    go.drugbank.com/drugs/DB11102
    ApprovedInvestigational

    It is typically administered as a source of nutritional support where oral nutrition is inadequate or cannot be tolerated. … N-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. [DB00135] is a non-essential amino acid with a polar side group.

    Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSION
  7. Drug

    Cetalkonium

    go.drugbank.com/drugs/DB11583
    ApprovedWithdrawn

    [A27143] It is a quaternary ammonium salt that acts as an antiseptic against a variety of bacteria and fungi. … [L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113]

  8. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    [A264768] Acoramidis has been in development since at least 2013. … [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.

  9. Drug

    Technetium Tc-99m disofenin

    go.drugbank.com/drugs/DB09164
    ApprovedWithdrawn

    It is available as an intravenous injection in a preparation kit under the name Hepatolite. … However disofenin is the most commonly used iminodiacetic acid since it has a high liver to renal extraction and its hepatic uptake is not as highly dependent on serum bilirubin levels (a competitive inhibitor

  10. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD … [L50336] Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD.